Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. - Wikidata - awgldk - TriplyDB

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

http://www.wikidata.org/entity/Q38367830

about

Bacterial outer membrane vesicles and vaccine applications Review of meningococcal vaccines with updates on immunization in adults Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso.Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Con Solution conformation and flexibility of capsular polysaccharides from Neisseria meningitidis and glycoconjugates with the tetanus toxoid protein.Glycoconjugate vaccines.Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.Meningococcal Vaccines: Current Status and Emerging Strategies.

P2860

Q24568229-52E86951-C6EA-441D-B457-DE38716F663F Q28828692-CCD92D04-D010-42D2-AE80-CF6EE09B4041 Q33959308-499BB89F-D9A7-4E56-96D1-F3A2BBC9580F Q34363122-2C274E3F-6CB0-4CA0-A014-41EDFCBFEE9D Q37067275-1ED04CB9-E7F5-47B0-AE03-E32B805039EF Q37367010-0556A2B2-0F52-49D2-AD78-77A7CD5E607E Q38044755-50B1DD78-48E5-4694-8596-2E10B86022A4 Q38066532-6A9DC0F8-04D4-4726-9CC6-0A6F5A8C0DCE Q38118371-7C7918F5-633C-47FA-834A-3971ED8DE70D Q38743826-281A224F-C8E3-4382-9EA2-93C08C308097 Q49013708-4DB5ECCE-8B7A-448A-A129-08258093D85B Q52679153-85AA61CC-0F3F-4214-9589-CA4B2528D884

P2860

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

http://www.wikidata.org/entity/Q38367830

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

@en

type

label

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

@en

prefLabel

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

@en

P1433

Q38367830-D89503FC-A09F-432D-801F-326B080A0D8C

P1476

Q38367830-A1B28997-0244-4D92-8707-312A0EAE1445

P2093

Q38367830-65136CB6-9C9D-42FB-B89D-EFAFEE89F277

Q38367830-7A638EE6-CC36-44B2-AC73-1275A5768DD2

Q38367830-973330D6-EC9C-40CC-9214-302D8945FF53

Q38367830-B5A90ED8-2652-48EC-9369-0BE96D0E79D9

P2860

Q38367830-01CD59D6-1A65-4094-9D29-BAA2FC4B85E6

Q38367830-0255448F-F209-4938-8FD8-154E056FC002

Q38367830-0260B03B-5249-403E-AC93-C261E41A96C1

Q38367830-04F78324-A135-41EF-A768-DCFFAC3E5301

Q38367830-072DDA1A-F8A0-4368-8E6E-2C3D8336DC55

Q38367830-09290E67-5462-4504-90DE-3A6F9E2B0AFE

Q38367830-0AA705AF-BA61-4713-8520-D09D04EA5330

Q38367830-124DBF74-D82C-41A3-BCD9-17461B73C67B

Q38367830-1461FE43-02B8-461F-907F-B000FF828D89

Q38367830-1683AF4D-E077-41A3-B52F-DC38A803CE4D

P304

Q38367830-59304252-015B-4B9A-9706-3B78D8A9B342

P31

Q38367830-6AC7F25A-EA3C-4C2B-8341-12A831C21572

P356

Q38367830-60C90563-5B8D-4920-B80E-12195A1D8C42

P478

Q38367830-9A1FF44A-A00B-4773-B500-763058D17D41

P577

Q38367830-6BEA2034-280E-48D6-A6DD-8F1598382BBC

P5875

Q38367830-9CAA056C-1A92-46D5-9801-139FE958075B

P698

Q38367830-A6721500-7312-469E-9B32-868F4B85330E

P932

Q38367830-643262A4-6DF8-4B59-8564-B5F543E68FC6

P356

P1433

Advances in preventive medicine

P1476

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

@en

P2093

Jacqueline M Miller

http://www.w3.org/2001/XMLSchema#string

Marie Van Der Wielen

http://www.w3.org/2001/XMLSchema#string

Narcisa Mesaros

http://www.w3.org/2001/XMLSchema#string

Yaela Baine

http://www.w3.org/2001/XMLSchema#string

P2860

Serogroup W-135 meningococcal disease during the Hajj, 2000

Prospects for vaccine prevention of meningococcal infection

Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine

Novel vaccine strategies to T-independent antigens.

A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Review of meningococcal group B vaccines.

Epidemiological profile of meningococcal disease in the United States

P304

846756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2011/846756

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51710717

http://www.w3.org/2001/XMLSchema#string

P698

21991444

http://www.w3.org/2001/XMLSchema#string

P932

3170757

http://www.w3.org/2001/XMLSchema#string